Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

被引：0
|
作者：
Kumar Rajagopalan
David Peereboom
G. Thomas Budd
Thomas Olencki
Siva Murthy
Paul Elson
Denise McLain
Ronald Bukowski
机构：
[1] The Cleveland Clinic Foundation,Department of Hematology and Medical Oncology
[2] The Cleveland Clinic Cancer Center,Experimental Therapeutics Program
[3] The Cleveland Clinic Cancer Center,Department of Biostatistics
来源：
Investigational New Drugs | 1998年 / 16卷
关键词：
FUDR; hormone-refractory metastatic prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Circadian administration of chemotherapy has been reported to decrease toxicity and possibly enhance efficacy. Between March 1991 and December 1993, 18 evaluable patients with progressive, hormone-refractory metastatic prostate cancer were treated in this phase II trial of circadian infusion floxuridine (FUDR). The drug was delivered through a central venous catheter using a CADD-Plus computerized pump such that approximately 70% of the drug was administered between 3 and 9 p.m. and the rest (30%) was administered between 9 p.m. and 3 p.m. The dose of FUDR was 0.15 mg/kg/day × 14 days every 4 weeks. A total of 79 complete cycles was administered.
引用
收藏
页码：255 / 258
页数：3
相关论文
共 50 条
  • [31] TREATMENT IN METASTATIC PROSTATE CANCER WITH HORMONE REFRACTORY
    Vitello, S.
    Vacirca, F.
    Triglia, E.
    Giarratano, G.
    EJC SUPPLEMENTS, 2008, 6 (14): : 126 - 126
  • [32] HORMONE REFRACTORY METASTATIC PROSTATE-CANCER
    STERNBERG, CN
    ANNALS OF ONCOLOGY, 1992, 3 (05) : 331 - 335
  • [33] A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
    Moore, M. M.
    Stockler, M.
    Lim, R.
    Mok, T. S. K.
    Millward, M.
    Boyer, M. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (05) : 845 - 850
  • [34] A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
    M. M. Moore
    M. Stockler
    R. Lim
    T. S. K. Mok
    M. Millward
    M. J. Boyer
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 845 - 850
  • [35] CIRCADIAN INFUSION OF FLOXURIDINE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
    DEXEUS, FH
    LOGOTHETIS, CJ
    SELLA, A
    AMATO, R
    KILBOURN, R
    OGDEN, S
    STRIEGEL, A
    KWAN, J
    NEWMAN, RA
    JOURNAL OF UROLOGY, 1991, 146 (03): : 709 - 713
  • [36] A Phase II Trial of Triamcinolone with Hormone Therapy for Prostate Cancer (TRICREST) in Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer
    Ng, K.
    Sarker, S. -J.
    Greenwood, M.
    Gjafa, E.
    Alifrangis, C.
    Shamash, J.
    CLINICAL ONCOLOGY, 2019, 31 (02) : E23 - E24
  • [37] Phase II trial of vinorelbine in 120-hours continuous infusion in metastatic breast cancer refractory to anthracyclines
    Jara, C
    Alonso, C
    Fernandez, A
    GomezAldaravi, L
    Arroyo, M
    Bosch, C
    Tres, A
    Gonzalez, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 706 - 706
  • [38] A phase II study of temozolomide in hormone-refractory prostate cancer
    van Brussel, JP
    Busstra, MB
    Lang, MS
    Catsburg, T
    Schröder, FH
    Mickisch, GH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (06) : 509 - 512
  • [39] Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer
    Spitaleri, G.
    Matei, D. V.
    Curigliano, G.
    Detti, S.
    Verweij, F.
    Zambito, S.
    Scardino, E.
    Rocco, B.
    Nole, F.
    Ariu, L.
    De Pas, T.
    de Braud, F.
    De Cobelli, O.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 498 - 502
  • [40] A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer
    Flaig, Thomas W.
    Barqawi, Albaha
    Miller, Gary
    Kane, Madeleine
    Zeng, Chan
    Crawford, E. David
    Glode, L. Michael
    CANCER, 2006, 107 (02) : 266 - 274
12345